Ocular manifestations of graft-versus-host disease
- PMID: 24227989
- PMCID: PMC3770225
- DOI: 10.1016/j.sjopt.2013.06.007
Ocular manifestations of graft-versus-host disease
Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) has evolved over the past two decades to become the standard of care for hematologic and lymphoid malignancies. Major ocular complications after allogeneic HSCT have been increasing in number and severity. Graft-versus-host disease (GVHD) remains a major cause of ocular morbidity after allogeneic HSCT. The main objective of this review is to elucidate the ocular complications in patients developing GVHD following HSCT. Ocular complications secondary to GVHD are common and include dry eye syndrome, acquisition of ocular allergy from donors with allergic disorders. Eyelid changes may occur in GVHD leading to scleroderma-like changes. Patients may develop poliosis, madarosis, vitiligo, lagophthalmos, and entropion. The cornea may show filamentary keratitis, superficial punctate keratitis, corneal ulcers, and peripheral corneal melting which may lead to perforation in severe cases. Scleritis may also occur which can be anterior or posterior. Keratoconjunctivis sicca appears to be the most common presentation of GVHD. The lacrimal glands may be involved with mononuclear cell infiltration of both the major and accessory lacrimal glands and decrease in tear production. Severe dry eye syndrome in patients with GVHD may develop conjunctival scarring, keratinization, and cicatrization of the conjunctiva. Therapy of GVHD includes systemic immunosuppression and local therapy. Surgical treatment in refractory cases includes surgical intervention to improve the manifestation of GVHD of the eye. This may include tarsorrhapy, prose lenses, punctal occlusions and corneal transplantation.
Keywords: Graft-versus-host disease; Ocular; Transplantation.
Figures








Similar articles
-
Umbilical Cord Blood Platelet Lysate Eyedrops for the Treatment of Severe Ocular Surface Disorders in Graft vs. Host Disease Patients: Clinical Study.Life (Basel). 2024 Oct 5;14(10):1268. doi: 10.3390/life14101268. Life (Basel). 2024. PMID: 39459568 Free PMC article.
-
A plethora of ocular surface manifestations in a multidisciplinary ocular graft-versus-host disease unit.Sci Rep. 2022 Sep 23;12(1):15926. doi: 10.1038/s41598-022-19990-z. Sci Rep. 2022. PMID: 36151252 Free PMC article.
-
A Review of Ocular Graft-Versus-Host Disease.Optom Vis Sci. 2017 May;94(5):545-555. doi: 10.1097/OPX.0000000000001071. Optom Vis Sci. 2017. PMID: 28422804 Review.
-
Keeping an 'eye' on ocular GVHD.Clin Exp Optom. 2022 Mar;105(2):135-142. doi: 10.1080/08164622.2021.1971047. Epub 2021 Sep 19. Clin Exp Optom. 2022. PMID: 34538201 Review.
-
[Clinical characteristics and correlative factors of dry eye disease associated with graft-versus-host disease].Zhonghua Yan Ke Za Zhi. 2023 Apr 11;59(4):295-301. doi: 10.3760/cma.j.cn112142-20220801-00370. Zhonghua Yan Ke Za Zhi. 2023. PMID: 37012593 Chinese.
Cited by
-
Scleral Lens and Prosthetic Replacement of the Ocular Surface Ecosystem Utilization in Ocular Graft-versus-Host Disease: A Survey Study.Clin Ophthalmol. 2021 Dec 25;15:4829-4838. doi: 10.2147/OPTH.S337824. eCollection 2021. Clin Ophthalmol. 2021. PMID: 34992343 Free PMC article.
-
Acute exacerbation of ocular graft-versus-host disease and anterior uveitis after COVID-19 vaccination.BMC Ophthalmol. 2023 Aug 18;23(1):360. doi: 10.1186/s12886-023-03103-z. BMC Ophthalmol. 2023. PMID: 37596535 Free PMC article.
-
Contact lenses in dry eye disease and associated ocular surface disorders.Indian J Ophthalmol. 2023 Apr;71(4):1142-1153. doi: 10.4103/IJO.IJO_2778_22. Indian J Ophthalmol. 2023. PMID: 37026246 Free PMC article. Review.
-
Novel Applications of Mesenchymal Stem Cell-derived Exosomes for Myocardial Infarction Therapeutics.Biomolecules. 2020 May 2;10(5):707. doi: 10.3390/biom10050707. Biomolecules. 2020. PMID: 32370160 Free PMC article. Review.
-
International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update.Bone Marrow Transplant. 2024 Jun;59(6):717-741. doi: 10.1038/s41409-023-02190-2. Epub 2024 Feb 27. Bone Marrow Transplant. 2024. PMID: 38413823 Free PMC article. Review.
References
-
- Bleakley M.R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer. 2004;4:371–380. - PubMed
-
- Goulmy E., Schipper R., Pool J., Blokland E., Falkenburg J.H., Vossen J. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 1996;334:281–285. - PubMed
- Lee S.J., Schubert M.M. Graft-vs-host disease. Crit Rev Oral Biol Med. 1997;8:201–216. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous